Pelthos Therapeutics Inc (PTHS) Institutional Buying & Selling Tracker (Q2 2026)

PTHS ranks #7976 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

24 institutions disclose a position in PTHS, but none treat it as a major bet — even Murchinson Ltd., its most concentrated holder, allocates just 1.2% of its own portfolio to it.

Pale Fire Capital SE has added to its PTHS position for two straight quarters, increasing it by $114.0K to reach $365.1K today.

PTHS is up 0.8% today, and institutions have been net buyers of $11.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PTHS reported a net loss of $86.4M over the trailing twelve months.

• Not yet profitable — net loss of $86.4M over the trailing twelve months
• Net income declined year over year, from -$9.0M to -$86.4M
• Operating cash flow was negative, using $22.6M in cash
• Current ratio of 2.05x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.35x equity — a highly leveraged balance sheet worth noting